ClinicalTrials.gg
CompletedNCT00917592DANC-05Updated Sep 28, 2023

Trial Assessing the Efficacy of a Short Course of Intravenous Antibiotic Followed by Oral Antibiotic in Uncomplicated Acute Diverticulitis

A Phase 4 interventional study of amoxicillin plus clavulanic acid and amoxicillin plus clavulanic acid in Diverticulitis, sponsored by Consorci Sanitari de Terrassa. Completed at 1 site in Spain. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2023-09-28.

Sponsored by Consorci Sanitari de Terrassa · Phase 4, Interventional, and Treatment

Phase
Phase 4
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Study summary

Medical treatment of uncomplicated acute diverticulitis is not standardized and there is an enormous diversity in clinical practice. The investigators' aim was to demonstrate that uncomplicated diverticulitis can be managed with oral amoxicillin plus clavulanic acid with a short hospital admission.

Read the detailed description

A prospective randomized trial was established to compare patients with uncomplicated diverticulitis who received oral antibiotic after a short course of intravenous antibiotic, with those who received intravenous antibiotic for a longer period. We included 50 patients, 25 in each group. Patients in group 1 begun oral antibiotic as soon as they improved and were discharged the day after. Patients in group 2 received intravenous antibiotic for 7 days. Both groups received oral antibiotic at discharge. The endpoint of the study was "failure of treatment" which was defined as the impossibility of discharging on the expected day, emergency admission or hospital readmission.

02

Conditions studied

  • Diverticulitis

Browse trials for

Keywords

  • Diverticulitis
03

In context

Diverticulitis

125 studies on the registry are indexed under Diverticulitis; 22 are open to participants now.

This study's enrollment of 50 is below the median of 120 across 63 interventional studies indexed under Diverticulitis.

Browse Diverticulitis studies →

Lead sponsor

Consorci Sanitari de Terrassa is the lead sponsor of 41 studies on the registry; 15 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • clinical diagnosis of uncomplicated acute diverticulitis confirmed by a computed tomography (CT) scan within 24-48 hours

Exclusion Criteria (prerandomization):

  • patients
  • pregnant women
  • clinical suspicion or CT confirmation of complicated acute diverticulitis
  • performance score less than 50%
  • allergy to penicillin

Exclusion Criteria (postrandomization):

  • withdrawal of the trial
  • CT confirmation of complicated acute diverticulitis
  • CT not conforming to acute diverticulitis
  • CT performed 72 hours after the admission
  • adverse reaction to the antibiotic
  • bacteriemia
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Short intravenous amoxicillin plus clavulanic acid

    Intravenous antibiotic 48 hours followed by oral antibiotic for 10 days

    Drug: amoxicillin plus clavulanic acid

  • Active comparator
    Long intravenous amoxicillin plus clavulanic acid

    Intravenous antibiotic for 7 days followed by oral antibiotic for 5 days

    Drug: amoxicillin plus clavulanic acid

Interventions

  • Drugamoxicillin plus clavulanic acid

    Drug pages: Amoxicillin · Clavulanic Acid

    intravenous amoxicillin plus clavulanic acid 1 gr every 8 hours 48 hours followed by oral amoxicillin plus clavulanic acid 1 gr every 8 hours for 10 days

  • Drugamoxicillin plus clavulanic acid

    Drug pages: Amoxicillin · Clavulanic Acid

    intravenous amoxicillin plus clavulanic acid for 7 days followed by oral antibiotic for 5 days

06

What researchers measure

Primary outcomes

  1. failure of treatment

    Time frame: the 4th day (group 1) or the 8th day (group 2)

Secondary outcomes

  1. emergency admission or hospital readmission for reasons related to the previous diverticulitis

    Time frame: 30 days after discharge

07

Study locations

1 site
  • Consorci Sanitari de Terrassa
    Terrassa, Barcelona 08227, Spain
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00917592
Lead sponsor
Consorci Sanitari de Terrassa
Responsible party
Yolanda Ribas (Principal Investigator, Consorci Sanitari de Terrassa) — Principal investigator
First posted
Jun 10, 2009
Start date
Dec 2005
Primary completion
May 2008
Completion
Oct 2008
Last update
Sep 28, 2023

Study contacts

Yolanda Ribas, MD, PhD
principal investigator · Consorci Sanitari de Terrassa

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Amoxicillin · Clavulanic Acid

Start the discussion